Browse Articles

A significant percentage of cancer survivors develop a second primary cancer. Using data of deceased patients provided by the Peninsula Regional Medical Center, Li and Holdai conducted a retrospective statistical analysis to investigate whether the type of the first cancer affects the occurrence time and type of the second primary cancer.

The authors assess incidence and mortality rates of two cancer types in relation to trihalomethane pollutant concentrations in drinking water.

The authors develop a machine learning method to reduce misclassification of objects in safety-critical applications such as medical diagnosis.

The authors investigate whether human blood cancers carrying mutations in DNA repair genes possess increased sensitivity to common chemotherapy drugs cisplatin or gemcitabine.

The current five-year survival rate of metastasized prostate cancer is only 30% and occurs in every one in nine men. Researchers have shown that people with a type of dwarfism called Laron’s Syndrome are immune to cancer due to their low levels of insulin-like growth factor-1 (IGF-1). For this reason, experimentally modifying the level of IGF-1 could provide better insight into whether lowering the levels of IGF-1 in prostate cancer cell lines (e.g. PC-3) could be an effective treatment to reduce their rates of proliferation and migration and increase apoptosis. We selected three compounds, which researchers have shown decrease IGF-1 levels, to test and combine to determine which is the most promising.

This study used single-cell RNA sequencing to examine whether B cells can predict response to pembrolizumab and radiation therapy in patients with triple-negative breast cancer.

Although the 5-year survival rate for colorectal cancer is below 10%, it increases to greater than 90% if it is diagnosed early. We hypothesized from our research that analyzing non-synonymous single nucleotide variants (SNVs) in a patient's exome sequence would be an indicator for high genetic risk of developing colorectal cancer.

In this study, the authors looked at a proto-oncogene, KRAS, and searched for molecules that are predicted to be able to bind to the inactive form of KRAS. They found that a modified version of Irbesartan, a derivative of benzimidazole, showed the best binding to inactive KRAS.

Cancer cells rely heavily on glycolysis, but how they respond when glucose is reintroduced after acute starvation is not well understood. Using fluorescence lifetime imaging microscopy, students tracked metabolic changes in HeLa cells and found a rapid shift toward glycolysis within 20 minutes of glucose reintroduction, followed by heterogeneous recovery toward oxidative phosphorylation. These results highlight metabolic flexibility and variability in cancer cells, offering insights relevant to treatment resistance and therapeutic design.

Here the authors sought to better understand glioma, cancer that occurs in the glial cells of the brain with gene expression profile analysis. They considered the expression of complement system genes across the transcriptional and IDH-mutational subtypes of low-grade glioma and glioblastoma. Based on their results of their differential gene expression analysis, they found that outcomes vary across different glioma subtypes, with evidence suggesting that categorization of the transcriptional subtypes could help inform treatment by providing an expectation for treatment responses.